Friedreich's ataxia

5 trials 2 recruiting MedDRA PT
5 Registered trials
2 Recruiting
5 Unique sponsors
4 Unique IMPs
4 Commercial trials
Drug classes (ATC)
N Neurology/Psychiatry (ATC N) 2
— ATC code not specified 3
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Phase III: 3 Phase II: 3

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

3 trials
  • Biogen Idec Research Limited Commercial
    OMAVELOXOLONE
    2025-520896-13-00 8 countries 2025 n=127 Orphan
    Recruiting
  • Larimar Therapeutics Inc. Commercial
    NOMLABOFUSP
    2025-521628-31-00 1 country n=18 Orphan
    Pending
  • PTC Therapeutics Inc. Commercial
    VATIQUINONE
    2024-516505-23-00 4 countries 2023 n=34 Orphan
    Recruiting

Phase II

3 trials
  • Reata Pharmaceuticals Inc. Commercial
    OMAVELOXOLONE
    2024-517436-22-00 2 countries 2016 n=21 Orphan
    Ended
  • Dipartimento Di Neuroscienze E Scienze Riproduttive Ed Odontostomatologiche Universita Degli Studi Di Napoli Federico II Academic
    DIMETHYL FUMARATE
    2022-503016-16-00 1 country 2023 n=40
    Ended
  • Reata Pharmaceuticals Inc. Academic
    OMAVELOXOLONE
    2024-517436-22-00 2 countries 2016 n=21 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Reata Pharmaceuticals Inc. Commercial 2 Phase II 0
Biogen Idec Research Limited Commercial 1 Phase III 1
Larimar Therapeutics Inc. Commercial 1 Phase III 0
PTC Therapeutics Inc. Commercial 1 Phase III 1
Dipartimento Di Neuroscienze E Scienze Riproduttive Ed Odontostomatologiche Universita Degli Studi Di Napoli Federico II Academic 1 Phase II 0
New trials by year
2023
2
2025
1
← All indication landscapes